SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jaybe4/26/2016 8:46:44 PM
3 Recommendations

Recommended By
glass 0.5 full
tktom
xr1

  Read Replies (1) of 4474
 
Univ. Colorado now recruiting for AP32788...

Should start to see quite a bit of buzz from KOL's on this trial, which I estimate will complete enrollment by end of year (105 pts. out of 6,000 US incident pool). Looks like each cohort could lead to a separate pivotal trial in 2018. With activity against all EGFR mutations Cohort 4 could see upside in EGFR 2L in T790m-negative patients (45% of 2L), a relatively underserved population. Disappointing to see at AACR that Cohort 2 (Her2) will require higher (2-3X) dose, safety profile permitting.

clinicaltrials.gov
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News